Literature DB >> 17882920

American Rhinologic Society member survey on "maximal medical therapy" for chronic rhinosinusitis.

Marc G Dubin1, Cindy Liu, Sandra Y Lin, Brent A Senior.   

Abstract

BACKGROUND: "Maximal medical therapy" is the standard of care for chronic rhinosinusitis (CRS) treatment before the recommendation for surgery. However, this therapy is not consistent. Therefore, as a first step in determining the role of the disparate "maximal medical" treatments for CRS, American Rhinologic Society (ARS) members were surveyed.
METHODS: A survey was mailed to all nonresident members of the ARS (n=723). Focusing on the time period before surgical intervention is first considered for CRS patients, the survey assessed types of therapies, frequency of use, details on antibiotic and steroid usage, use of computed tomography (CT), and demographic data of respondents. All responses were anonymous.
RESULTS: Three hundred eight surveys were returned (43%). A majority of respondents used oral antibiotics and nasal steroids "almost always (>90%)". Oral antibiotics, oral steroids, nasal steroids, saline irrigation, and allergy testing were most commonly used at least "usually (50-90%)". The median antibiotic length was 3.1-4 weeks. The mean peak prednisone dose was 51.7 mg when oral steroids were used. Therapies that were rarely or never used by the majority included oral antifungals, antifungal spray, antibiotic spray, antibiotic nebulizer, steroid nebulizer, and i.v. antibiotics.
CONCLUSION: Oral antibiotics (median, 3.1-4 weeks) and nasal steroids are used >90% of the time by a majority of ARS members for maximal medical treatment of CRS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17882920     DOI: 10.2500/ajr.2007.21.3047

Source DB:  PubMed          Journal:  Am J Rhinol        ISSN: 1050-6586


  19 in total

1.  Coagulase-negative Staphylococcus culture in chronic rhinosinusitis.

Authors:  Zi Zhang; Nithin D Adappa; Ebbing Lautenbach; Alexander G Chiu; Laurel J Doghramji; Noam A Cohen; James N Palmer
Journal:  Int Forum Allergy Rhinol       Date:  2014-11-03       Impact factor: 3.858

2.  A Computational Study of Nasal Spray Deposition Pattern in Four Ethnic Groups.

Authors:  Jarrod A Keeler; Aniruddha Patki; Charles R Woodard; Dennis O Frank-Ito
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-08-13       Impact factor: 2.849

Review 3.  The Role of the Fibroblast in Inflammatory Upper Airway Conditions.

Authors:  Stephen L Ball; Derek A Mann; Janet A Wilson; Andrew J Fisher
Journal:  Am J Pathol       Date:  2015-12-10       Impact factor: 4.307

Review 4.  Comprehensive review on endonasal endoscopic sinus surgery.

Authors:  Rainer K Weber; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

Review 5.  Microbiome of the paranasal sinuses: Update and literature review.

Authors:  Jivianne T Lee; Daniel N Frank; Vijay Ramakrishnan
Journal:  Am J Rhinol Allergy       Date:  2016 Jan-Feb       Impact factor: 2.467

6.  Trends in endoscopic sinus surgery rates in the Medicare population.

Authors:  Giridhar Venkatraman; Donald S Likosky; Weiping Zhou; Samuel R G Finlayson; David C Goodman
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-05

Review 7.  Is there a future for biologics in the management of chronic rhinosinusitis?

Authors:  Kent Lam; Robert C Kern; Amber Luong
Journal:  Int Forum Allergy Rhinol       Date:  2016-04-22       Impact factor: 3.858

8.  Culture-inappropriate antibiotic therapy decreases quality of life improvement after sinus surgery.

Authors:  Zi Zhang; James N Palmer; Knashawn H Morales; Timothy J Howland; Laurel J Doghramji; Nithin D Adappa; Alexander G Chiu; Noam A Cohen; Ebbing Lautenbach
Journal:  Int Forum Allergy Rhinol       Date:  2014-01-10       Impact factor: 3.858

9.  Quantification of airflow into the maxillary sinuses before and after functional endoscopic sinus surgery.

Authors:  Dennis O Frank; Adam M Zanation; Vishal H Dhandha; Kibwei A McKinney; Gitanjali M Fleischman; Charles S Ebert; Brent A Senior; Julia S Kimbell
Journal:  Int Forum Allergy Rhinol       Date:  2013-09-05       Impact factor: 3.858

Review 10.  Oral steroid therapy in chronic rhinosinusitis with and without nasal polyposis.

Authors:  Brittany E Howard; Devyani Lal
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.